RayKnowChina Research Map
Shortlist0

ShenyangChina Medical University (Shenyang)

Fourth Affiliated Hospital of China Medical University

中国医科大学附属第四医院

Listed for 6 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Fourth Affiliated Hospital of China Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌11 papers led
  2. Stomach cancer胃癌20 papers led
  3. Osteosarcoma骨肉瘤2 papers led
  4. Neuroblastoma神经母细胞瘤2 papers led
  5. Ewing sarcoma尤文肉瘤0 papers led
  6. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 11 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.07%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 5520222023: 1120232024: 2220242025: 222025

4 hospitals in Shenyang for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapyRecurrence & prognosisImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineNeurologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led11
  1. Research advances on amino acid starvation interventions for hepatocellular carcinoma.2025Biochimica et biophysica acta. Reviews on cancer
  2. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification.2025Gut microbesFree full text
  3. Investigating autophagy and intricate cellular mechanisms in hepatocellular carcinoma: Emphasis on cell death mechanism crosstalk.2024Cancer letters
  4. Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma.2024Cell death & diseaseFree full text
  5. VEZF1, destabilized by STUB1, affects cellular growth and metastasis of hepatocellular carcinoma by transcriptionally regulating PAQR4.2023Cancer gene therapy
  6. LAMTOR1 degrades MHC-II via the endocytic in hepatocellular carcinoma.2022CarcinogenesisFree full text
  7. METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma.2022Human cell
  8. ALDH2 Hampers Immune Escape in Liver Hepatocellular Carcinoma through ROS/Nrf2-mediated Autophagy.2022Inflammation
  9. An emerging role of radiation‑induced exosomes in hepatocellular carcinoma progression and radioresistance (Review).2022International journal of oncologyFree full text
  10. Histone deacetylase 2 regulates STAT1-dependent upregulation of atypical chemokine receptor 3 to induce M2 macrophage migration and immune escape in hepatocellular carcinoma.2022Molecular immunology
  11. LINC00511 drives invasive behavior in hepatocellular carcinoma by regulating exosome secretion and invadopodia formation.2021Journal of experimental & clinical cancer research : CRFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 20 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 3320222023: 4420232024: 4420242025: 332025

5 hospitals in Shenyang for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapy & targeted drugsEarly detection & endoscopySurgery
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiation oncologyGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led20
  1. A facile dual-drug delivery system using cellulose-based microgel/hydrogel for enhanced gastric cancer therapy.2025Colloids and surfaces. B, Biointerfaces
  2. Autoimmune diseases and risk of gastrointestinal cancer: an umbrella review of meta-analyses of observational studies.2025International journal of surgery (London, England)
  3. The cardiac glycoside periplocymarin sensitizes gastric cancer to ferroptosis via the ATP1A1-Src-YAP/TAZ-TFRC axis.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. Ubiquitin-specific proteases: From biological functions to potential therapeutic applications in gastric cancer.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications.2024BiomoleculesFree full text
  6. Extracellular vesicles mediated gastric cancer immune response: tumor cell death or immune escape?2024Cell death & diseaseFree full text
  7. Antibody-drug conjugates in gastric cancer: from molecular landscape to clinical strategies.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  8. Assessment of the efficacy and safety of carbon nanoparticles-guided lymph node dissection in gastric cancer surgery: a systematic review and meta-analysis.2023International journal of clinical oncology
  9. Association between hospital surgical case volume and postoperative mortality in patients undergoing gastrectomy for gastric cancer: a systematic review and meta-analysis.2023International journal of surgery (London, England)Free full text
  10. The members of the miR-148/152 family inhibit cancer stem cell-like properties in gastric cancer via negative regulation of ITGA5.2023Journal of translational medicineFree full text
  11. Adherence to the Mediterranean Diet and Risk of Gastric Cancer: A Systematic Review and Meta-Analysis.2023NutrientsFree full text
  12. circFCHO2 promotes gastric cancer progression by activating the JAK1/STAT3 pathway via sponging miR-194-5p.2022Cell cycle (Georgetown, Tex.)Free full text
  13. Profiling and Characterization of microRNAs Responding to Sodium Butyrate Treatment in Gastric Cancer Cells.2022Combinatorial chemistry & high throughput screening
  14. The burden and trend of gastric cancer and possible risk factors in five Asian countries from 1990 to 2019.2022Scientific reportsFree full text
  15. Long noncoding RNA CYTOR triggers gastric cancer progression by targeting miR-103/RAB10.2021Acta biochimica et biophysica Sinica
  16. MSC-AS1 induced cell growth and inflammatory mediators secretion through sponging miR-142-5p/DDX5 in gastric carcinoma.2021AgingFree full text
  17. HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer.2021Cancer gene therapyRCT
  18. Upregulation of HOXC9 generates interferon-gamma resistance in gastric cancer by inhibiting the DAPK1/RIG1/STAT1 axis.2021Cancer scienceFree full text
  19. Screening and Validation of the Hypoxia-Related Signature of Evaluating Tumor Immune Microenvironment and Predicting Prognosis in Gastric Cancer.2021Frontiers in immunologyFree full text
  20. The novel role and function of LINC01235 in metastasis of gastric cancer cells by inducing epithelial-mesenchymal transition.2021Genomics

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

9 hospitals in Shenyang for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Immunotherapy of osteosarcoma based on immune microenvironment modulation.2024Frontiers in immunology
  2. 3D-printing magnesium-polycaprolactone loaded with melatonin inhibits the development of osteosarcoma by regulating cell-in-cell structures.2021Journal of nanobiotechnology
Earlier papers (2016–2020)9
  1. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.2020Drug delivery
  2. Reduction-responsive sulfur dioxide polymer prodrug nanoparticles loaded with irinotecan for combination osteosarcoma therapy.2020Nanotechnology
  3. Primary Ewing's sarcoma of the vertebral body: A case report.2019Medicine
  4. Combination of subxiphoid and intercostal uniportal video-assisted thoracoscopic surgery for bilateral lung lesions: report of two cases and review of the literature.2017Postgraduate medicine
  5. Genetic polymorphisms in MMP 2, 3 and 9 genes and the susceptibility of osteosarcoma in a Chinese Han population.2016Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  6. Silencing FAT10 inhibits metastasis of osteosarcoma.2016International journal of oncology
  7. MicroRNA-603 functions as an oncogene by suppressing BRCC2 protein translation in osteosarcoma.2016Oncology reports
  8. CD151 knockdown inhibits osteosarcoma metastasis through the GSK-3β/β-catenin/MMP9 pathway.2016Oncology reports
  9. Interleukin 10 gene -1082A/G polymorphism is associated with osteosarcoma risk and poor outcomes in the Chinese population.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

6 hospitals in Shenyang for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPediatrics

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Shenyang for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Primary Ewing's sarcoma of the vertebral body: A case report.2019Medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

7 hospitals in Shenyang for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中国医科大学附属第四医院

Fourth Affiliated Hospital of China Medical University

沈阳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
fourth affiliated hospital of China medical university

Suggest a correctionDownload the data